Summary: Dr Jonathan Cohen presents a timely update on the pharmacotherapy of glycaemic control and other factors that modify cardiovascular risk for people with type 2 diabetes. Metformin is usually the first line, but what comes next?
Summary: Dr Jonathan Cohen presents a timely update on the pharmacotherapy of glycaemic control and other factors that modify cardiovascular risk for people with type 2 diabetes. Metformin is usually the first line, but what comes next?